Mirae Asset Global Investments Co. Ltd. Lowers Stock Position in AstraZeneca PLC $AZN

Mirae Asset Global Investments Co. Ltd. cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.5% in the third quarter, Holdings Channel.com reports. The fund owned 280,564 shares of the company’s stock after selling 13,253 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in AstraZeneca were worth $21,525,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in AZN. Chapin Davis Inc. increased its holdings in AstraZeneca by 3.3% in the 3rd quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock valued at $291,000 after purchasing an additional 120 shares during the last quarter. CoreCap Advisors LLC boosted its position in shares of AstraZeneca by 30.6% during the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after buying an additional 125 shares during the period. Highline Wealth Partners LLC grew its stake in shares of AstraZeneca by 32.0% in the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock valued at $41,000 after buying an additional 129 shares in the last quarter. Traub Capital Management LLC grew its stake in shares of AstraZeneca by 3.3% in the third quarter. Traub Capital Management LLC now owns 4,115 shares of the company’s stock valued at $316,000 after buying an additional 130 shares in the last quarter. Finally, Aaron Wealth Advisors LLC raised its holdings in shares of AstraZeneca by 0.6% in the 3rd quarter. Aaron Wealth Advisors LLC now owns 21,215 shares of the company’s stock valued at $1,628,000 after buying an additional 136 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, January 21st. Wall Street Zen lowered shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. HSBC restated a “buy” rating and issued a $108.00 price objective on shares of AstraZeneca in a report on Wednesday, December 10th. Citigroup started coverage on shares of AstraZeneca in a research report on Tuesday. They issued a “buy” rating for the company. Finally, Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, January 6th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Stock Performance

Shares of AZN stock opened at $92.59 on Friday. The company has a market cap of $287.20 billion, a P/E ratio of 30.76, a PEG ratio of 1.60 and a beta of 0.34. The firm has a fifty day moving average price of $92.26 and a 200 day moving average price of $84.14. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $96.51.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The company had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. During the same period in the previous year, the business earned $2.08 EPS. AstraZeneca’s revenue for the quarter was up 12.0% on a year-over-year basis. Sell-side analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Trending Headlines about AstraZeneca

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: AstraZeneca announced a $15 billion investment plan in China through 2030 to expand manufacturing and R&D, signaling a major commitment to China growth and capacity that could boost long?term sales and local partnerships. AstraZeneca sets out $15 billion China investment during Starmer visit
• Positive Sentiment: China’s CSPC Pharmaceutical signed a deal with AstraZeneca to develop long?acting peptide medicines for obesity/weight?related conditions — strengthens AZN’s obesity pipeline and a China commercialization route. China’s CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy
• Positive Sentiment: Citigroup initiated coverage of AZN with a Buy recommendation — an analyst catalyst that can support demand for the ADR among institutional investors. Citigroup initiates coverage of AstraZeneca PLC – depositary receipt (AZN) with buy recommendation
• Positive Sentiment: Bank of America Securities also initiated a Buy rating on AZN, adding further sell?side support. Bank of America Securities Initiates a Buy Rating on AstraZeneca (AZN)
• Positive Sentiment: AstraZeneca expanded academic collaboration with the University of Virginia to accelerate pre?clinical innovation, supporting pipeline discovery and future R&D productivity. University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation
• Neutral Sentiment: Analyst and media pieces are reassessing AZN valuation after mixed recent share performance — useful context but not a direct catalyst. Assessing AstraZeneca (LSE:AZN) Valuation After Mixed Recent Share Price Performance
• Neutral Sentiment: Coverage of PM Keir Starmer’s China trip notes AstraZeneca as part of the UK delegation — political/diplomatic context that underpinned the China investment announcement. Airbus, AstraZeneca and HSBC executives join UK’s Starmer on high-stakes China trip
• Neutral Sentiment: Reported short?interest data for January appears inconsistent/insignificant (zeros/NaN) and doesn’t provide a clear signal about bearish positioning at this time.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.